ASH 2019 | Columba study update: subcutaneous daratumumab in R/R MM
Saad Usmani
• 7 Dec 2019
Saad Usmani, MD, FACP, Levine Cancer Institute, Charlotte, NC, gives an update on the COLUMBA study (NCT03277105), a randomized, open-label, phase III trial evaluating the efficacy and safety of subcutaneous (SC) versus intravenous (IV) daratumumab in patients with relapsed/refractory (R/R) multiple myeloma (MM). With longer follow-up, data continues to support that SC and IV administration of daratumumab have similar safety profiles, however, SC administration has a reduced treatment burden due to a shorter administration duration. This interview was recorded at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
